Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1795194 Target Snapshot

Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha · SINGLE PROTEIN · Homo sapiens

1,324Compounds
133Assays
2Approved Drugs
752.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt P48426. Use UniProt P48426 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P48426 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha as ChEMBL target CHEMBL1795194, mapped to UniProt P48426. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1795194
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P48426
Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha is the right protein anchor across sources, using UniProt P48426 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPhosphatidylinositol 5-phosphate 4-kinase type-2 alpha
UniProt AccessionP48426
Component TypeProtein
Sequence Length406 aa

Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha, mapped to UniProt P48426. Sequence length is 406 aa.

Mapped IDP48426
Review namePhosphatidylinositol 5-phosphate 4-kinase type-2 alpha
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

2
Approved
2
Phase II
Assay Mix

Activity Type Distribution

IC50541.0
EC5011.0
KD200.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4802045 9.0 IC50 1.0 Preclinical
CHEMBL5280127 8.7 IC50 2.0 Preclinical
CHEMBL5276719 8.3 IC50 5.0 Preclinical
CHEMBL5270765 8.15 IC50 7.0 Preclinical
CHEMBL5288342 8.0 IC50 10.0 Preclinical
CHEMBL5290005 7.89 IC50 13.0 Preclinical
CHEMBL5271652 7.85 IC50 14.0 Preclinical
CHEMBL5277824 7.72 IC50 19.0 Preclinical
CHEMBL5277633 7.7 IC50 19.95 Preclinical
CHEMBL5288492 7.52 IC50 30.0 Preclinical
Distribution

pChEMBL Value Distribution

38
5.0
71
5.5
46
6.0
51
6.5
24
7.0
15
7.5
8
8.0
6
8.5
2
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

PALBOCICLIB
CHEMBL189963
Approved 2015
Assay Landscape

Assay Landscape

134
Total Assays
191
Tested Compounds
2
Assay Types
Binding — 132 assays, 191 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 58 52 6.0
cell-based format 42 70 6.4
subcellular format 27 4 5.8
assay format 5 65 6.1
Functional — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine